F Fuzkk Atlas of Asia, the Middle East, Canada, Australia and Africa
#256Extended selection 101–300

AFT Pharmaceuticals

New Zealand · Australia and New Zealand

Consumer health / OTC

Manufacturing profile

Consumer health / OTC

Country: New Zealand

Macro-region: Australia and New Zealand

Selection basis

The company is placed in positions 101–300 as a manufacturer, biotech, specialty-pharma, generics or CDMO company with practical relevance to the existing FUZKK catalog.

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Representative manufacturing and QC chain

  1. 1High-volume blending, granulation and filling
  2. 2Liquid, semi-solid or oral-solid formulation
  3. 3Packaging and labelling
  4. 4Assay, microbiology and stability
  5. 5Supplier control, incoming inspection and complaint trends

Relevant FUZKK packages

China: national essential medicines QC packageGlobal API & Biosimilars QC Suite

Product/API utilities

—

Lumex — instrumental QC

System Suitability Parameters Checker

LabEx — laboratory QC

Assay & Impurity HPLC Quality CheckerDissolution Apparatus 1 & 2 Quality CheckerContent Uniformity Quality CheckerMicrobial Enumeration (TAMC/TYMC) Quality CheckerSpecified Microorganisms Quality CheckerStability Condition Monitoring Quality Checker

Medical Devices — equipment and software lifecycle

Packaging Integrity CheckerSupplier Evaluation CheckerCalibration Status CheckerProcess Validation CheckerChange Control Impact CheckerRequirement Traceability CheckerData Integrity Security Checker

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Methodology